RANDOMIZED, NON-COMPARATIVE, PHASE II TRIAL OF BEVACIZUMAB AND TRABECTEDIN WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER (ROC) WOMEN

被引：0
|
作者：
Colombo, N. [1 ]
Nicoletto, M. O. [2 ]
Lissoni, A. [3 ]
Scambia, G. [4 ]
Tognon, G. [5 ]
Negri, E. [6 ]
Galli, F. [6 ]
Biagioli, E. [6 ]
Rulli, E. [6 ]
Fossati, R. [6 ]
D'Incalci, M. [6 ]
机构：
[1] IEO European Inst Oncol, Gynecol Oncol, Milan, Italy
[2] IRCCS, Inst Oncol Veneto IOV, Padua, Italy
[3] Osped San Gerardo, Oncol, Monza, Italy
[4] Osped Policlin Gemelli, Oncol, Rome, Italy
[5] Univ Brescia, Oncol, Brescia, Italy
[6] IRCCS, Ist Ric Farmacol Mario Negri, Milan, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2017年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO7-0059
引用
收藏
页码：1471 / 1471
页数：1
相关论文
共 50 条
  • [21] EXTENDING THE PLATINUM-FREE INTERVAL (PFI) WITH TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN A PATIENT WITH PARTIALLY PLATINUM-SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC)
    Giovannoni, S.
    Marchetti, C.
    Verkhovskaia, S.
    De Benedetto, A.
    Cortesi, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1357 - 1357
  • [22] Targeting autophagy in platinum-sensitive relapsed ovarian cancer: randomized phase II trial of hydroxychloroquine with chemotherapy with biomarker correlation
    Goenka, Luxitaa
    Dubashi, Biswajit
    Kayal, Smita
    Rajappa, Medha
    Manivannan, Prabhu
    Chakkalakkoombil, Sunitha Vellathussery
    Gochhait, Debasis
    Chaturvedula, Latha
    Pradeep, S.
    Anandaradje, Annuja
    Goud, Alladi Charanraj
    Ganesan, Prasanth
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [23] A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
    Oza, Amit M.
    Estevez-Diz, Maria
    Grischke, Eva-Maria
    Hall, Marcia
    Marme, Frederik
    Provencher, Diane
    Uyar, Denise
    Weberpals, Johanne I.
    Wenham, Robert M.
    Laing, Naomi
    Tracy, Michael
    Freshwater, Tomoko
    Lee, Mark A.
    Liu, Ji
    Qiu, Jingjun
    Rose, Shelonitda
    Rubin, Eric H.
    Moore, Kathleen
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4767 - 4776
  • [24] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
    Gladieff, L.
    Ferrero, A.
    De Rauglaudre, G.
    Brown, C.
    Vasey, P.
    Reinthaller, A.
    Pujade-Lauraine, E.
    Reed, N.
    Lorusso, D.
    Siena, S.
    Helland, H.
    Elit, L.
    Mahner, S.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1185 - 1189
  • [25] A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma
    Rose, PG
    Smrekar, M
    Fusco, N
    GYNECOLOGIC ONCOLOGY, 2005, 96 (02) : 296 - 300
  • [26] A phase I study of lapatinib in combination with carboplatin in women with recurrent platinum-sensitive ovarian carcinoma
    Kimball, K. J.
    Numnum, T. M.
    Kirby, T. O.
    Zamboni, W. C.
    Estes, J. M.
    Barnes, M. N.
    Matei, D.
    Alvarez, R. D.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S60 - S60
  • [27] Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
    González-Martín, AJ
    Calvo, E
    Bover, I
    Rubio, MJ
    Arcusa, A
    Casado, A
    Ojeda, B
    Balañá, C
    Martínez, E
    Herrero, A
    Pardo, B
    Adrover, E
    Rifá, J
    Godes, MJ
    Moyano, A
    Cervantes, A
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 749 - 755
  • [28] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
    Aghajanian, Carol
    Goff, Barbara
    Nycum, Lawrence R.
    Wang, Yan V.
    Husain, Amreen
    Blank, Stephanie V.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 10 - 16
  • [29] Phase II trial of docetaxel(D)/carboplatin(C) as treatment for first relapsed platinum-sensitive stage III/IV ovarian cancer.
    Goff, B
    Paley, PJ
    Gooley, T
    Holmberg, LA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 461S - 461S
  • [30] A phase 3 trial of weekly farletuzumab combined with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse
    Weil, Susan C.
    Jenkins, Michele
    Hoffman, Kimberly
    CANCER RESEARCH, 2012, 72
12345